Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABI-009 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABI-009 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABI-009 | DRUG | nab-rapamycin |
Inclusion Criteria: Each subject must meet the following criteria to be enrolled in this study. 1. Male and female patients with histologically or cytologically confirmed diagnosis of cancer which is not amenable to curative therapy. 2. Patients with advanced non-hematologic malignancies for whom ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABI-009 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for oncology indications, specifically advanced non-hematologic malignancies. The drug is not yet approved and remains under clinical investigation.
ABI-009 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this investigational small molecule for the treatment of solid tumors.
ABI-009 is in Phase 1 clinical development. It is an investigational drug for solid tumors and has not been approved by regulatory authorities. The drug is still in early-stage clinical trials to evaluate its safety and potential efficacy.
ABI-009 has one completed clinical trial, NCT00635284, titled 'ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies.' This Phase 1 study enrolled 27 patients with solid tumors in the United States and was not randomized, double-blind, or biomarker-selected.
ABI-009 is a small molecule therapeutic being developed for solid tumors. Its specific molecular target has not been disclosed in available information, so its precise mechanism of action is not detailed here.